Billionaire investor Carl Icahn said on Tuesday his nominees for Clorox Co's
The move is the latest salvo in an intensifying battle for Clorox, where Icahn launched a proxy fight after the board rejected two of his buyout offers, the last one worth $10.52 billion, or $80 a share. Icahn is Clorox's largest shareholder, with a 9.51 percent stake.
Icahn also sought to resolve questions about how he would finance his latest $78 per share bid, saying he would pay at least half in cash and the rest in bonds.
That effectively means Clorox shareholders would have to partly finance his bid. Icahn did not give any details of who would issue the unsecured notes or what the terms would be.
For his earlier bids, Icahn had secured a highly confident letter of financing from Jefferies Group Inc
Doubts remained about the latest move by Icahn, whose bid is widely seen as an attempt to see if any other buyer will emerge.
The shares of the 99-year-old company, which makes a range of products from bleach to Burt's Bees lotions, were up 2.7 percent, but were nearly $8 below Icahn's offer of $78 per share.
Other potentially strategic buyers have continued to sit on the sidelines despite his efforts to provoke them, Morningstar analyst Erin Lash said.
Icahn is a billionaire many times over -- his net worth was pegged at $12.5 billion by Forbes as of March -- but even for him a deal on his current terms would mean writing a massive check.
Clorox said the proposal substantially undervalues the company and is not credible.
Icahn is now looking to fund up to half of the purchase price of his inadequate, highly conditional proposal by borrowing from Clorox stockholders, it said.
Clorox is the latest battle for the 75-year-old investor, whose very foray into a stock is known to strike fear in the hearts of corporate directors.
But the fortunes of the corporate raider-turned-activist are far from even and results are not guaranteed, as he draws on his well-known playbook.
On Tuesday, he agreed to shed his stake in Lions Gate Entertainment Corp
Earlier this month, he lost a proxy battle at Forest Laboratories Inc
Icahn first offered to buy Clorox in July for $76.50 per share, a 12 percent premium at the time. After Clorox rejected the bid and adopted a poison pill to make an unwanted takeover more expensive, Icahn raised his bid but was again spurned.
Icahn stepped up the pressure earlier this month, saying he wanted to replace the entire Clorox board. He said he wanted to nominate himself, his son and nine other people for election to the board at the company's next annual shareholder meeting.
Icahn said on Tuesday that a deal would be subject to the approval of the new Clorox board and would be voted on by Clorox shareholders.
The Clorox shareholders should have the right to decide for themselves whether to accept my bid or a better bid, which I believe will be forthcoming from the sale process, he said.
But analysts and bankers said Icahn may have trouble persuading Clorox investors the bid was high enough.
Using the multiple that Unilever Plc
Chances are low the bid will pass muster with Clorox's existing board or investors, these experts said.
Clorox has shown no interest, so lowering the bid and offering notes isn't that compelling, said an investment banker, who is not involved in the deal.
I don't think this move is going to motivate anyone to change their mind. Even if Icahn won board control, it doesn't mean anyone will bid, said the banker, who was not authorized to speak to the media.
Clorox shares closed up $1.89 at $70.52 on Tuesday.